Cramer: Neutral on MannKind's (MNKD) Afrezza

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says MannKind  (MNKD) is difficult to gauge because many people felt its inhaled insulin drug Afrezza would fail. As a result, 28% of the float was short and any positive news would send the stock upward.

Cramer says some believe the stock will go down again almost immediately. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock because Mannkind has already spent so much money trying to get Afrezza developed. 

Cramer remains "completely neutral" on this because "sometimes it's just better to admit that you don't know where something's going."

Must Watch: Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind in Free Fall After Changes to Insulin Product, Sales Force